NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia

Abstract Background Acute myeloid leukaemia (AML) comprises a group of heterogeneous and aggressive haematological malignancies with unsatisfactory prognoses and limited treatment options. Treatments targeting B-cell lymphoma-2 (BCL-2) with venetoclax have been approved for patients with AML, and ve...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Ying Lu, Xia Jiang, Youhong Li, Fenglin Li, Mengting Zhao, Ye Lin, Lili Jin, Haihui Zhuang, Shuangyue Li, Peipei Ye, Renzhi Pei, Jie Jin, Lei Jiang
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2024-09-01
Цуврал:	Journal of Translational Medicine
Нөхцлүүд:	AML NL101 Venetoclax Apoptosis MCL-1 c-Myc
Онлайн хандалт:	https://doi.org/10.1186/s12967-024-05647-0
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!